IOB Institute of Oncology - Hospital Quironsalud Barcelona

Barcelona 8023

1 studies enrolling now · 3 studies all time

What they study most

Advanced Breast Cancer, Advanced Lung Cancer, Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, HER2 Mutation-Related Tumors, HER2-Positive Primary Breast Cancer, HER2-positive Advanced Breast Cancer, HER2-positive Metastatic Breast Cancer, HR-positive, HER2-negative Advanced Breast Cancer, Head and Neck Squamous Cell Carcinoma, KRAS Mutant Metastatic Colorectal Cancer

Studies at this site

• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination — Running, not enrolling